Payment overview · 2025
General Payments
$465.37
24 reported records · 14 companies
Healthcare provider profile · identity verified
Shaun M Jayakar, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · WARREN, MI · NPI 1770747594
Verified facts
What the public records show
CMS Open Payments records show Shaun M Jayakar, MD received $465.37 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.64 | 16.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.10 | 9.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.44 | 9.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.77 | 9.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.91 | 8.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.62 | 8.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.67 | 6.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.50 | 6.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.37 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.34 | 4.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.41 | 4.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.11 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.55 | 3.8% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.94 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $465.37 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.64 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.74 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $45.10 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.44 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.67 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 555 | 123 |
| Omeprazole | Omeprazole | 397 | 80 |
| Metformin Hcl | Metformin Hcl | 329 | 72 |
| Losartan Potassium | Losartan Potassium | 282 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 253 | 63 |
| Montelukast Sodium | Montelukast Sodium | 253 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 57 |
| Lisinopril | Lisinopril | 193 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 183 | 36 |
| Potassium Chloride | Potassium Chloride | 161 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 31 |
| Trazodone Hcl | Trazodone Hcl | 160 | 38 |
| Trulicity | Dulaglutide | 160 | 30 |
| Carvedilol | Carvedilol | 158 | 31 |
| Famotidine | Famotidine | 133 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 27 |
| Simvastatin | Simvastatin | 129 | 37 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 121 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 29 |
| Eliquis | Apixaban | 116 | 27 |
| Nifedipine Er | Nifedipine | 116 | 27 |
| Furosemide | Furosemide | 109 | 33 |
| Gabapentin | Gabapentin | 107 | 28 |
| Buspirone Hcl | Buspirone Hcl | 91 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 20 |
| Tradjenta | Linagliptin | 78 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 30 |
| Atenolol | Atenolol | 73 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 70 | 24 |
| Hydrocortisone | Hydrocortisone | 69 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 13 |
| Allopurinol | Allopurinol | 65 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Ozempic | Semaglutide | 60 | 11 |
| Alprazolam | Alprazolam | 59 | 13 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 59 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 56 | suppressed |
| Ibuprofen | Ibuprofen | 54 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 53 | 39 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 53 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Spironolactone | Spironolactone | 50 | 14 |
| Bupropion Hcl | Bupropion Hcl | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 17 |
| Sertraline Hcl | Sertraline Hcl | 44 | 11 |
| Bumetanide | Bumetanide | 43 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Lidocaine | Lidocaine | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 11 |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Prednisone | Prednisone | 40 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 13 |
| Methocarbamol | Methocarbamol | 37 | 12 |
| Methylprednisolone | Methylprednisolone | 35 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 17 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 11 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Baclofen | Baclofen | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 16 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Movantik | Naloxegol Oxalate | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Betamethasone Valerate | Betamethasone Valerate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $465.37 · 24 records | Novo Nordisk Inc | BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Korlym, Ozempic, REPATHA, REXULTI, Rybelsus, Sunosi, VOQUEZNA, VRAYLAR, XIFAXAN, XYWAV, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error